Projects per year
Search results
-
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study:A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with orwithout Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients withDefici
Abdelrahim, M., Bernicker, E. H., Darcourt, J., Heyne, K. & Singh, M.
3/1/14 → 2/28/39
Project: Non Profit
-
EAY131 - Molecular Analysis for Therapy Choice (MATCH)
Bernicker, E. H., Chang, J. C., Darcourt, J., Heyne, K., Kamat, A. A., Pingali, S. R. & Singh, M.
9/20/16 → 9/20/41
Project: Federal Funding Agencies
-
A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OFASPIRIN AS ADJUVANT THERAPY FOR HER2 NEGATIVE BREAST CANCER: THE ABCTRIAL
Arentz, C., Abdelrahim, M., Bernicker, E. H., Chang, J. C., Heyne, K., Niravath, P. A., Singh, M. & Zhang, J.
12/8/16 → 12/7/41
Project: Non Profit
-
A phase III, multicenter, randomized, study of atezolizumab/placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer
Kamat, A. A., Alaniz, A., Bernicker, E. H., Darcourt, J., Heyne, K., Singh, M., Suri, A. & Zaid, T.
3/13/18 → 3/12/43
Project: Non Profit
-
CTSU - IRB SUBMISSIONA Phase III Trial To Evaluate The Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-Cd22 Monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL.
Abdelrahim, M., Bernicker, E. H., Chang, J. C., Heyne, K., Niravath, P. A., Singh, M. & Zhang, J.
3/6/20 → 3/5/45
Project: Non Profit
-
ALLIANCE A221602: OLANZAPINEWITH ORWITHOUT FOSAPREPITANT FOR THE PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC): A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Darcourt, J., Bernicker, E. H., Chang, J. C., Geyer, C. E., Heyne, K. & Niravath, P. A.
3/6/20 → 3/5/45
Project: Non Profit
-
Sample and Data Collection for Houston Methodist Cancer Center Research
Chang, J. C., Bernicker, E. H., Darcourt, J., Heyne, K., Niravath, P. A. & Singh, M.
4/9/20 → …
Project: Clinical Trial
-
An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
Singh, M., Abdelrahim, M., Heyne, K., Niravath, P. A. & Zhang, J.
7/25/22 → …
Project: Clinical Trial
-
Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy
Zhang, J., Chan, E. Y., Gibbs, J. M., Heyne, K., Kim, M. P., Singh, M. & Sultenfuss, M. A.
9/16/21 → …
Project: Clinical Trial
-
Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients
Zhang, J., Haque, W. M., Heyne, K., Shadle, K. M. & Singh, M.
9/25/19 → …
Project: Clinical Trial
-
Stem Cell: Biomarkers Including Putative Stem Cells Markers in Human Breast Cancers
Chang, J. C., Heyne, K., Niravath, P. A., Singh, M. & Templeton, S.
3/20/14 → …
Project: Clinical Trial
-
LEAP-012 - MERCK (7902-012, Site No. 0784) Safety and Efficacy of Lenvatinib (E7080 / MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable / Non-metastatic Hepatocellular Carcinoma (MK-7902-012 / E7080-G000-318 / LEAP-012)
Kodali, S., Abdelrahim, M., Ghobrial, R. M., Gibbs, J. M., Heyne, K., Saharia, A. & Victor, III, D. W.
3/27/20 → …
Project: Clinical Trial
-
Neoadjuvant Combination Therapy of Lenvima® plus Transcatheter Arterial Chemoembolization (TACE) for Transplant-Eligible Patients with Large Hepatocellular Carcinoma
Abdelrahim, M., Connor, A. A., Ghobrial, R. M., Graviss, E. A., Heyne, K., Kodali, S., Moore, L. W., Singh, M. & Victor, III, D. W.
5/12/23 → …
Project: Clinical Trial
-
A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
Abdelrahim, M., Chang, J. C., Heyne, K., Niravath, P. A., Singh, M. & Zhang, J.
5/2/22 → …
Project: Clinical Trial